Check out new publication!
Currently there are no disease-specific approved therapies for non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH); however, several treatments are under development.
A recently published study aimed to estimate the cost-effectiveness of hypothetical innovative therapies and assess the health economic consequences of their future availability for patients.